Mattel Reiterates FY23 Guidance

2023 Guidance Mattel's full year 2023 guidance remains: (in millions,    

2023 Guidance

Mattel’s full year 2023 guidance remains:

(in millions,  

 

   

except EPS and percentages)

 

FY2023 Guidance

 

FY2022

Net Sales  

Comparable

(Constant Currency)

 

$5,435

Adjusted Gross Margin  

~ 47%

 

45.9%

Adjusted EPS  

$1.10 – $1.20

 

$1.25

Adjusted EBITDA  

$900 – $950

 

$968

Adjusted Tax Rate  

25 – 26%

 

24%

Capital Expenditures  

$175 – $200

 

$187

Free Cash Flow  

> $400

 

$256

Total
0
Shares
Related Posts
Read More

CymaBay Therapeutics Announced Collaboration with Kaken Pharmaceutical to Develop and Commercialize Seladelpar in Japan for Primary Biliary Cholangitis; Kaken to Make Upfront Payment To Cymabay Of ~$34M Plus Milestone Payments Up To ~$128.4M And Royal…

CymaBay Therapeutics, Inc. (NASDAQ: CBAY) announced today that it has entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. ("Kaken") for the development and commercialization in Japan of CymaBay's investigational drug seladelpar for the treatment of primary biliary cholangitis ("PBC").

CBAY